A Multicenter, Open-Label Study of Sebelipase Alfa in Patients With Lysosomal Acid Lipase Deficiency

Trial Profile

A Multicenter, Open-Label Study of Sebelipase Alfa in Patients With Lysosomal Acid Lipase Deficiency

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 May 2017

At a glance

  • Drugs Sebelipase alfa (Primary)
  • Indications Wolman disease
  • Focus Adverse reactions
  • Sponsors Alexion Pharmaceuticals; Synageva BioPharma
  • Most Recent Events

    • 22 Dec 2016 Planned End Date changed from 1 Feb 2018 to 1 Dec 2017.
    • 22 Dec 2016 Planned primary completion date changed from 1 Feb 2018 to 1 Dec 2017.
    • 21 Apr 2016 Planned End Date changed from 1 Apr 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top